Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...

Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month to end a short-lived partnership to sell its Wegovy weight-loss drug ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

We recently published Market on Mute? Not for These 10 Stocks With Surprising Gains. Hims & Hers Health, Inc. (NYSE:HIMS) is ...

Hims & Hers Health Inc. board members and executives failed to tell shareholders that its Novo Nordisk A/S Wegovy ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that securities class action lawsuits have been fil ...

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations about Hims’ compounding and deceptive marketing practices.

The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in.  | Novo ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...